TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04554706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-phone delivered Treatment for Excessive Rumination
Description: This is a one-month three-arm clinical control trial to reduce the rumination and interpersonal impairment link.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-phone delivered Treatment for Excessive Rumination
Description: This is a one-month three-arm clinical control trial to reduce the rumination and interpersonal impairment link.
Study: NCT06109701

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement with ultrasonic device and scaling with plastic curettes
Description: Supragingival and subgingival debridement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement with erythritol based air-polishing powde
Description: Supragingival and subgingival debridement
Study: NCT05933473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: percutaneous intervention to oseal LAD with or without LM stenting
Study: NCT05872412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 1 hour on day 1 every three weeks for four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 1 hour on day 1 every three weeks for four cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 IV over 1 hour weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 IV over 1 hour weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles
Study: NCT05754125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Di-Leucine Supplement
Description: Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA Supplement
Description: Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Supplement
Description: Participants will consume a amino acid supplement containing Collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
Study: NCT05136560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intervention drugs would be administered for 1 or 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intervention drugs would be administered for 1 or 2 days.
Study: NCT06191549

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (a-tDCS)
Description: Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Young and older healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.~Stroke participants in each group will receive a four-week of the assigned brain stimulation combined with visuomotor stepping training and treadmill training

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (a-tDCS)
Description: Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Young and older healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.~Stroke participants in each group will receive a four-week of the assigned brain stimulation combined with visuomotor stepping training and treadmill training

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (a-tDCS)
Description: Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Young and older healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.~Stroke participants in each group will receive a four-week of the assigned brain stimulation combined with visuomotor stepping training and treadmill training

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (a-tDCS)
Description: Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Young and older healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.~Stroke participants in each group will receive a four-week of the assigned brain stimulation combined with visuomotor stepping training and treadmill training
Study: NCT05332704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4685
Description: -Part A: Single ascending doses of ONO-4685 as a single IV dose (Cohort A1-A5).
Study: NCT06227260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thai massage, Thai massage with pure coconut oil, Thai massage with oil mixed with Snake fruit extract, Control, Facial mask with Snake fruit extract, Control jelly, Jelly with Snake fruit juice
Description: Interventions among the 3 studies were categorized as other.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai massage, Thai massage with pure coconut oil, Thai massage with oil mixed with Snake fruit extract, Control, Facial mask with Snake fruit extract, Control jelly, Jelly with Snake fruit juice
Description: Interventions among the 3 studies were categorized as other.
Study: NCT05562414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will perform six high-intensity intervals (95% HRmax) at high pedalling rates of 80-100 rounds per minute (rpm) for 60-90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20 watts, 60-80rpm) aimed to return to 60% HRmax (approximately 1.5-2 min). The duration of the HIIT bout is approximately 21 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MCT
Description: Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will continuously train at 60% HRmax and pedal at 60-80 rounds per minute. The duration of the MCT bout is 26 minutes.
Study: NCT06440902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is given In patients with NeoRAS WT
Study: NCT05012033

Intervention type: OTHER
Intervention: No intervention - prednisolone is taken as part if routine clinical care.
Description: Prednisolone given orally prior to taking timed samples for levels

Intervention type: OTHER
Intervention: No intervention - prednisolone is taken as part if routine clinical care.
Description: Prednisolone given orally prior to taking timed samples for levels

Intervention type: OTHER
Intervention: No intervention - prednisolone is taken as part if routine clinical care.
Description: Prednisolone given orally prior to taking timed samples for levels
Study: NCT06326099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Online Binge Eating and Drinking Intervention
Description: The intervention is an online mobile phone program developed by our research team. It builds upon efficacious brief alcohol interventions with college students by addressing underlying loss of control, impulsivity, and emotion regulation through the use of videos, interactive activities, and psychoeducation.
Study: NCT05332704

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: -Part A: Single ascending doses of placebo as a single IV dose (Cohort A1-A5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4685
Description: -Part B: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort B1 and B2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: -Part B: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort B1 and B2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4685
Description: -Part C: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort C1 and C2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: -Part C: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort C1 and C2).
Study: NCT06034340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LET Gel after STAR Particle Application (Right or Left Arm)
Description: STAR particles are made of titanium dioxide, a widely used and safe ceramic material found in sunscreens, cosmetics, and paint. The particles vary in concentration and length in order to find the optimal concentration and length. Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying a STAR particle preparation to the volar surface of the antecubital fossa.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LET Gel Application without STAR Particle Application (Contralateral Arm)
Description: Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying aloe gel (control condition) to the volar surface of the antecubital fossa of the contralateral arm to the one receiving the STAR particle preparation.
Study: NCT06457568

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement
Description: The blood pressure measurement was taken simultaneously by two observers using mercury sphygmomanometer and by a supervisor using the tested device, CONTEC08C.
Study: NCT06375356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Strength exercises (3-4 sets each exercise) videos delivered electronically, participant self-tracks and self-progresses based on effort reported.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Strength exercises (3-4 sets each exercise) videos delivered electronically, participant self-tracks and self-progresses based on effort reported.
Study: NCT05768932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL0891
Description: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL0891
Description: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL0891
Description: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL0891
Description: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
Study: NCT06639178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DECLARAN cream
Description: Patients will apply 1 mL of DECLARAN cream, as a single pressure dispensing (1 for hands, 1 for feet), 2 times/day on hands and feet, starting 3 days before the beginning of treatment with capecitabine and for the first 24 consecutive weeks of treatment.
Study: NCT05694247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorNeat KPro
Description: The optical component of the CorNeat KPro will be implanted into a circular disc of the cornea (as performed in standard penetrating keratoplasty surgery) and the skirt component will be embedded under a 360º conjunctival flap.
Study: NCT06455033

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Diaphragm Release Technique
Description: The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. During exhalation, the therapist deepens their contact towards the inner costal margin while maintaining resistance. As the respiratory cycles continues, the therapist progressively increases the depth of their contact within the costal margin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Exercise
Description: Sit up straight in a chair lengthen the distance between your navel and sternum. Keep your shoulders relax.~Keep the pelvis in neutral position (Sit on your sitting bones). Place your hands at either side of your lower ribs. Breath in slowly through your nose. As you inhale feel your ribs expanding outwards and upwards. During inhalation is generated expansion of the trunk in three directions front , sides and back.~Breath out from your nose. As you exhale feel your lower ribs moving inwards.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Exercise
Description: Sit up straight in a chair lengthen the distance between your navel and sternum. Keep your shoulders relax.~Keep the pelvis in neutral position (Sit on your sitting bones). Place your hands at either side of your lower ribs. Breath in slowly through your nose. As you inhale feel your ribs expanding outwards and upwards. During inhalation is generated expansion of the trunk in three directions front , sides and back.~Breath out from your nose. As you exhale feel your lower ribs moving inwards.
Study: NCT05471609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa oral formulation A
Description: Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa oral formulation B
Description: Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa oral formulation C
Description: Outer sachet 50mg CD/200mg LD and inner sachet 50mg CD /200mg LD
Study: NCT05363995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-Sleep & BioClock Intervention
Description: The 'i-Sleep \& BioClock' intervention aims at improving sleep and the biological clock among university students. It is incorporates evidence-based techniques such as cognitive behavioural therapy for insomnia (CBTi). The intervention has a duration of 5 weeks and consists of five modules:~1. psychoeducation on insomnia, sleep hygiene and the biological clock,~2. stimulus control and sleep restriction therapy,~3. worrying and relaxation exercises,~4. cognitive therapy to change dysfunctional thoughts about sleep, and~5. summary module, relapse prevention, and plan for the future.~The intervention is supported by e-coaches who give personalized written feedback. Students will fill in a sleep \& light exposure diary daily.
Study: NCT05633238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Search Information Type (target or distractor information)
Description: Participants will have information about targets, distractors, or neither in different blocks of the intervention.
Study: NCT04116151

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)
Description: Application on the affected skin of the cream to be tested

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Usual treatment
Description: Application on the affected skin of the emollient and moisturizing substance
Study: NCT06029582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR headset
Description: Virtual Reality Headset
Study: NCT06603181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: exercise and splint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: exercise and splint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: exercise and splint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phonophoresis
Description: exercise, splint and phonophoresis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave therapy
Description: exercise, splint and ESWT
Study: NCT06591572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port robotic transanal total mesorectal excision
Description: Rectal resection by transanal TME with single-port robotic surgery
Study: NCT05768932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL0891
Description: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL0891
Description: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
Study: NCT06591572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic transanal total mesorectal excision
Description: Rectal resection by transanal TME with Laparoscopic surgery
Study: NCT06596499

Intervention type: DEVICE
Intervention: CH-VAD
Description: The CH-VAD pump is a fully magnetically levitated (maglev), centrifugal continuous-flow blood pump.
Study: NCT04849364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 BID Orally 14 days on and 7 days off Cycle = 21 days; Total of 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 BID Orally 14 days on and 7 days off Cycle = 21 days; Total of 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 BID Orally 14 days on and 7 days off Cycle = 21 days; Total of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib Cycle 1: 0.75 mg then Cycle 2-8: 1 mg Cycle = 21 days; Total of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib Cycle 1: 6 mg then Cycle 2-8: 9mg Orally 21 days on Cycle = 21 days; Total of 8 cycles
Study: NCT06613061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: The researcher has a breathing exercise certificate. In our study, the breathing exercise application consists of three stages: box breathing, sigh breathing and diaphragm breathing.~Patients will be asked to continue the breathing exercise application for 2 weeks and will be reminded to do the breathing exercises. Box and sigh breathing will be done 3 times a day (morning, noon and evening) every day for 2 weeks. Diaphragm breathing exercise will be applied for 2 minutes in the first week and 4 minutes in the second week.
Study: NCT06613087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot bath
Description: In the foot bath application, the feet will be kept in water at a constant temperature of 38-40 °C for about 20 minutes. During this time, the water temperature will be checked with a thermometer at intervals. Foot bath applications will be performed for 3 days, on the 2nd, 3rd and 4th days of hospitalization.
Study: NCT06614751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAT-2645 tablet
Description: The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAT-2645 tablet
Description: The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAT-2645 tablet
Description: The study set 6 dose level cohorts in dose escalation part.On C0D1, patient take DAT-2645 one time (Single use), The dosage is same as his enrolled cohort dose level. if no DLT, 7 days later(C1D1), patients will continue taking DAT-2645 tablet daily, dasage is same as before, 21days/cycle.
Study: NCT06616961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen
Description: In this study, the intervention involves administering semaglutide (Fitaro) to participants for weight management. The treatment protocol includes the following steps:~Initial Dose: Participants will start with a subcutaneous injection of semaglutide at a dose of 0.25 mg once weekly for the first four weeks to allow for tolerance and adjustment.~Dose Escalation: After the initial period, the dose will be increased at four-week intervals as follows:~Week 5: Increase to 0.5 mg Week 9: Increase to 1 mg Week 13: Increase to 1.7 mg Week 17: Increase to a maximum dose of 2.4 mg, if necessary, based on individual weight loss response and tolerability.
Study: NCT06616493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: measure the subjects' lower extremity biomechanical characteristics with 3 different conditions respectively (kinesio taping, placebo kinesio taping, no taping)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: kinesio taping
Description: measure the subjects' lower extremity biomechanical characteristics with 3 different conditions respectively (kinesio taping, placebo kinesio taping, no taping)
Study: NCT06617676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: Two electrodes will be place over the tibial nerve over the medial ankle. The electrical stimulation will be turned up to patient tolerance at a sensory level only.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: Two electrodes will be place over the tibial nerve over the medial ankle. The electrical stimulation will be turned up to patient tolerance at a sensory level only.